12 Dec 2023
Simcere Pharmaceutical Opens ‘Hong Kong Collaborative Innovation Center’ Accelerating R&D and Translation of Innovative Drugs
Key Takeaways
- HKSTP will join hands with Simcere to leverage Hong Kong's unmatched connectivity with mainland China, offering a world of opportunities.
- Listed on the HKEX in 2020, Simcere is the first batch of strategic enterprises of the Office for Attracting Strategic Enterprises (OASES) of the HKSAR Government.
- The ‘Hong Kong Collaborative Innovation Center’ will focus on four core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection.
Photo 1: Mr Gordon Cheung, AS for Innovation, Technology and Industry Bureau (fourth from left, first row), Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP (third from left, first row), Dr Grace Lau, Head of Institute for Translational Research of HKSTP (second from left, first row), Professor Lo Yuk Lam, President of HK Bio-Med Innotech Association (HKBMIA) (second from right, first row), Mr Song Ka Woon, Independent Non-Executive Director of Simcere Pharmaceutical Group Limited (fourth from right, first row), and Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group Limited (third from right, first row), were present at the opening ceremony.
Photo 2: Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP, said, “We shall join hands with Simcere and further leverage Hong Kong's strength of ‘bridging the mainland market and embracing global opportunities’.”
Photo 3: Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group, said, “We are looking forward to fostering innovative strategic partnerships between Simcere and academic institutions, industry partners and the Hong Kong government. We aim to facilitate the establishment of a collaborative innovation ecosystem for the pharmaceutical industry across Greater Bay Area and ultimately realises Simcere’s innovation strategy 2.0 of ‘Radiate into global markets with Hong Kong as our anchor point’.”